Skip to content
Drugs Targeting NTRKGabriele Wright2024-07-02T15:51:12-05:00
Drugs Targeting NTRK
- Vitrakvi (larotrectinib) – approved for stage 4 NSCLC patients with a fusion in NTRK as detected by a biomarker test.
- Rozlytrek (entrectinib) – approved for stage 4 NSCLC patients with a fusion in NTRK as detected by a biomarker test.
- Augtyro (repotrectinib) – approved for solid tumors, including NSCLC, for adults and children aged 12 years and older with a fusion in NTRK as detected by a biomarker test.
